Share This Page
Drug Price Trends for NDC 60429-0972
✉ Email this page to a colleague
Average Pharmacy Cost for 60429-0972
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60429-0972
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PRAZOSIN HCL 2MG CAP | Golden State Medical Supply, Inc. | 60429-0972-01 | 100 | 20.04 | 0.20040 | 2023-06-15 - 2028-06-14 | FSS |
| PRAZOSIN HCL 2MG CAP | Golden State Medical Supply, Inc. | 60429-0972-10 | 1000 | 193.50 | 0.19350 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60429-0972
Introduction
The National Drug Code (NDC) 60429-0972 pertains to a specified pharmaceutical product within the U.S. healthcare system. Analyzing its market landscape involves understanding its therapeutic use, patent status, manufacturing dynamics, competitive environment, pricing trends, and potential future valuation. Given the critical influence of regulatory, clinical, and commercial factors, a comprehensive and forward-looking approach is necessary for stakeholders assessing investment, supply chain, or strategic positioning.
Product Overview
The NDC 60429-0972 corresponds to a [insert specific drug name, formulation, and manufacturer], approved by the U.S. Food and Drug Administration (FDA). Its primary indication targets [specify the disease or condition], with a mechanism of action centered on [explain pharmacology]. Launched in [launch year], it has demonstrated [clinical efficacy, safety profile], positioning it within the [relevant therapeutic class] segment.
Market Landscape
1. Therapeutic Area and Patient Demographics
The drug addresses [describe disease prevalence, demographics]—a segment experiencing [growth, stabilization, decline] based on recent epidemiological data. The prevalence of [condition] is estimated at [number] cases nationally, with an annual treatment market value approximating [figures].
2. Regulatory Status and Patent Protection
The product holds FDA approval under NDA [number], with patent protections established until [date]. Patent exclusivity under the Hatch-Waxman Act, possibly supplemented by orphan drug designation or other regulatory rewards, grants the manufacturer a competitive advantage during exclusivity periods.
3. Manufacturing and Supply Chain Dynamics
Manufactured by [manufacturer], the drug benefits from scalable production capabilities. Market supply is currently stable; however, potential risks include raw material shortages, regulatory inspections, or manufacturing disruptions that could impact pricing and availability.
Competitive Environment
The drug operates within a competitive landscape comprising brand-name therapies, biosimilars, or generic counterparts, depending on patent expiry and regulatory pathway. Major competitors include [list primary competitors], which over the last [timeframe] have experienced *[market share shifts, price erosion, or stability].
The competitive edge of NDC 60429-0972 hinges on clinical superiority, pricing strategies, preferred prescribing status, or formulation advantages. Market penetration is primarily influenced by payor coverage and clinician preference.
Pricing Trends and Projections
1. Current Pricing Metrics
As of [most recent data date], the wholesale acquisition cost (WAC) for NDC 60429-0972 is approximately $[amount] per [unit]. Medicare and private payor reimbursement levels align accordingly, with patient co-pays varying based on formulary positioning.
2. Historical Price Movements
Over the past [number] years, the drug’s price has experienced mild inflationary adjustments, averaging [percentage]% annually. Price stabilization was observed following the initial patent expiry of [competitor], leading to increased market share for this product.
3. Market Drivers Impacting Future Pricing
- Patent and Exclusivity Status: Pending patent expiration in [year] may introduce generics, exerting downward pressure.
- Regulatory Developments: Potential approvals for combination therapies or new indications could enhance demand and justify premium pricing.
- Market Penetration: Increasing adoption by payors, driven by clinical efficacy, can sustain or elevate current price levels.
- Cost-effective Competition: Biosimilars or generics entering the market could drastically reduce prices.
- Reimbursement Policies: Changes in healthcare reimbursement, value-based pricing models, or formulary negotiations will influence achievable prices.
4. Future Price Projections
Analysts project that if patent exclusivity extends until [year] with no substantial generic competition, the drug’s pricing could maintain or slightly increase, reaching $[projected amount] per [unit] by [year, e.g., 2025]. Post-patent expiry, market prices are expected to decline by [percentage]% to [amount], driven by generic entry and intensified competitive pressure.
The adoption of value-based agreements and managed reimbursement frameworks could moderate pricing volatility, aligning costs more closely with clinical outcomes.
Revenue Forecasts and Market Share Outlook
Assuming current adoption rates and favorable reimbursement pathways, projected revenues for NDC 60429-0972 could reach $[amount] annually by [year], representing a compound annual growth rate (CAGR) of [percentage]% over the next five years, unless disrupted by new entrants or regulatory factors.
Market penetration is expected to grow, aided by clinician familiarity and payor inclusion, potentially capturing [percentage]% of the therapeutic niche within [region]. The upcoming patent cliff in [year] could, however, significantly alter this outlook.
Regulatory and Policy Impacts
Recent policy trends emphasizing value-based care, biosimilar pathways, and accelerated approvals could impact the market dynamics for this drug. Initiatives by CMS to reduce drug costs and increase generic utilization may exert downward pricing pressure post-patent expiration. Conversely, expanded indications or orphan status could sustain pricing premiums.
Key Factors Affecting Price and Market Share
- Patent expiration date and patent challenge outcomes.
- Introduction of biosimilars or generics.
- Regulatory approvals for expanded indications.
- Clinician and patient adoption rates.
- Reimbursement landscape and insurance coverage policies.
Conclusion
The market for NDC 60429-0972 remains promising, powered by its clinical profile, regulatory protections, and market positioning. Nonetheless, impending patent expiry and evolving competitive forces necessitate vigilant strategic planning. Price projections indicate stable to slightly increased pricing in the short term, with potential declines post-generic entry. Stakeholders should monitor patent statuses, regulatory developments, and market acceptance to optimize investment and commercialization strategies.
Key Takeaways
- The product currently commands a stable price point, reinforced by patent exclusivity and clinical demand.
- Anticipated patent expiry in [year] is poised to introduce generics, likely leading to significant price reductions.
- Market growth relies heavily on payor coverage, clinician adoption, and regulatory landscape shifts.
- Price projections suggest moderate increases pre-patent expiry, with potential contractions afterward.
- Strategic positioning should include preparing for patent cliff effects, exploring new indications, and engaging with payors early.
FAQs
Q1: What is the typical patent expiry for drugs like NDC 60429-0972?
A: In the U.S., patent protections generally last 20 years from the filing date, but effective market exclusivity often extends 8-12 years post-launch due to regulatory and patent challenges.
Q2: How do biosimilars impact pricing of biologic drugs like this one?
A: Biosimilars introduce competition, often reducing prices by 15-35%, consequently impacting revenue and market share.
Q3: What factors influence payor reimbursement levels for this drug?
A: Clinical effectiveness, cost-effectiveness analyses, negotiated formulary placement, and utilization management strategies.
Q4: Are there prospects for expanding the indications of this drug?
A: Regulatory submissions for additional indications can enhance utilization and justify premium pricing, contingent on successful clinical trials.
Q5: What role do healthcare policies and legislation play in the pricing forecast?
A: Policies favoring cost containment, drug price negotiations, and incentives for generics profoundly influence future pricing dynamics and market access.
References
- [Insert relevant regulatory filings, market reports, or scientific literature as sources]
More… ↓
